Latin America Ploughs Ahead With Joint Pricing Strategy
This article was originally published in Scrip
Pharmaceutical companies wanting to sell high-cost drugs in Latin America may find themselves talking with multiple countries at once to find a single acceptable price. Mercosur member and associate countries are wielding their collective might to secure lower prices through a new negotiation mechanism supported by the Pan American Health Organization / World Health Organization. Mercosur health ministers have already announced an offer from Gilead to supply its hepatitis C drug Sovaldi (sofosbuvir) and next up for discussion are likely to be costly cancer medicines.